HRZE Dose Adjustment in Renal Impairment
Yes, pyrazinamide (Z) and ethambutol (E) require dose adjustment in severe renal impairment (creatinine clearance <30 mL/min), while isoniazid (H) and rifampin (R) do not require adjustment.
Drug-Specific Recommendations
No Adjustment Required
Isoniazid (H): Standard dosing (300 mg daily or 900 mg three times weekly) regardless of renal function 11
- Hepatically metabolized with minimal renal clearance
Rifampin (R): Standard dosing (600 mg daily or 600 mg three times weekly) regardless of renal function 112
- Hepatically metabolized; not removed by hemodialysis
- Half-life remains unchanged in renal failure at doses ≤600 mg daily
Adjustment Required for CrCl <30 mL/min or Hemodialysis
Pyrazinamide (Z): Change from daily to 25-35 mg/kg three times weekly (not daily) 1111
- Although hepatically metabolized, toxic metabolites (pyrazinoic acid, 5-hydroxy-pyrazinoic acid) accumulate in renal insufficiency
- Significantly removed by hemodialysis (45% dialysate recovery) 3
Ethambutol (E): Change from daily to 20-25 mg/kg three times weekly (not daily) 1111
- Approximately 80% renally cleared; accumulates in renal insufficiency
- Critical adjustment to prevent optic neurotoxicity 4
Practical Implementation
For CrCl 30-50 mL/min
- Use standard doses but consider therapeutic drug monitoring (TDM) with serum concentrations at 2 and 6 hours post-dose to optimize dosing 11
- Insufficient data exist for definitive recommendations in this range
For Hemodialysis Patients
- Administer all medications post-dialysis on dialysis days 11
- Facilitates directly observed therapy
- Prevents premature drug clearance (especially pyrazinamide)
- Consider TDM to ensure adequate absorption without excessive accumulation
Critical Monitoring
- Close clinical surveillance is mandatory—TB patients with chronic renal failure have worse outcomes than those without renal failure 11
- Monitor for neurotoxicity, particularly with ethambutol (optic neuritis) and isoniazid (peripheral neuropathy) 4
- Supplement with pyridoxine (vitamin B6) 25-50 mg daily with isoniazid to prevent neuropathy
Common Pitfalls to Avoid
Do not reduce the dose—this lowers peak concentrations and compromises efficacy. Instead, increase the dosing interval to three times weekly for pyrazinamide and ethambutol 11
Do not assume all HRZE drugs need adjustment—only pyrazinamide and ethambutol require modification in severe renal impairment
Do not forget post-dialysis dosing—administering medications before dialysis results in drug removal and treatment failure
Borderline renal function requires assessment—obtain 24-hour urine collection to accurately define degree of insufficiency before making regimen changes 11
The evidence consistently demonstrates that maintaining therapeutic efficacy while preventing drug accumulation and toxicity requires this interval-based (not dose-based) adjustment strategy for renally cleared agents in the HRZE regimen.